Fakeeh Care debuts on TASI today

05/06/2024 Argaam Special
One of Fakeeh Care’s hospitals

One of Fakeeh Care’s hospitals


Dr. Soliman Abdulkader Fakeeh Hospital Co. (Fakeeh Care Group) will begin trading on the Saudi Exchange (Tadawul) today, June 5 under the symbol 4017 and ISIN Code SA562GSHUOH7, at SAR 57.5 a share.

 

The stock will have daily and static price fluctuation limits of ±30% and ±10%, respectively. These fluctuation limits will be applied during the first three days of listing. From the fourth trading day onwards, the daily price fluctuation limits will revert to ±10% and the static price fluctuation limit will no longer apply.

 

For More IPOs

 

This is the fourth listing on Saudi Arabia’s main market in 2024, after MBC Holding Group Ltd. listed on Jan. 8, Middle East Pharmaceutical Industries Co. (Avalon Pharma) on Feb. 27 and Modern Mills Co. on March 27.

 

Last year, TASI listed seven companies, including, Al Mawarid Manpower Co., Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma), Morabaha Marina Financing Co. (MRNA), First Milling Co., Lumi Rental Co., ADES Holding Co., and SAL Saudi Logistics Services Co., besides the listing of Alinma Hospitality REIT Fund.

 

With this listing, the number of companies listed on TASI reached 217, excluding real estate traded funds, which amount to 18.

 

The company offered 49.8 million shares, or 21.47% of its post-IPO capital, at SAR 57.5 per share. 90% of offered shares were allocated to participating parties, while the remaining 10% were allocated to retail investors.

 

The retail coverage reached 14.5x, while the tranche of participating parties was 119x subscribed.

 

A total of 1.34 million retail investors submitted applications to shares worth about SAR 4.15 billion.

 

Each retail investor received a minimum of three shares, while the remaining shares will be allocated pro rata, based on the demand size of every subscriber to total shares. The allotment ratio amounted to 1.4075%. 

 

Company Profile 

 

Headquartered in Jeddah, Fakeeh Care is a closed joint-stock Saudi company, founded as a sole proprietorship in 1978.

 

The company's main activities include owning, operating, and managing hospitals, clinics, and other healthcare facilities, as well as medical education and training centers, laboratories, radiology centers, and pharmacies.

Fakeeh Care has three segments: medical services, education, as well as trade and retail business. 

 

The group, one of the largest private sector healthcare providers in the Kingdom, has been operating in this field for over 45 years. It also enjoys widespread recognition across the Gulf region.

 

Fakeeh Care has nine branches in various cities within the Kingdom, including Makkah, Jeddah, and NEOM. The company owns three major subsidiaries and 11 minor subsidiaries.

 

Company Profile

Company

Dr. Soliman Abdulkader Fakeeh Hospital Co.

Market

TASI

Core Activities

Healthcare

Capital Pre-IPO

SAR 200 mln

Capital Post-IPO

SAR 232 mln

Number of Shares

200 mln

Number of shares after IPO

232 mln

Par Value

SAR 1/share

 

Major Shareholders

Shareholders

Before IPO

Post-IPO

Number of Shares

(mln shares)

Ownership (%)

Number of Shares

(mln shares)

Ownership (%)

Mazen Soliman Abdulkader Fakeeh

79.98

39.99%

71.42

 30.79%

Ammar Soliman Abdulkader Fakeeh

79.98

39.99%

71.42

 30.79%

Manal Soliman Abdulkader Fakeeh

39.99

20.00%

35.71

15.39%

Treasury shares*

--

--

2.00

0.86%

Employee Investment Fund Allocated Shares

--

--

1.60

0.69%

Public

--

--

49.80

21.47%

Total

200.0

100%

232.0

100%

*The company’s shareholders approved the issuance and retention of shares as treasury shares, which were allocated to the Employee Stock Incentive Program (ESIP) of the company and its subsidiaries.

Comments {{getCommentCount()}}

Be the first to comment

loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Most Read